Last reviewed · How we verify

NCT03572114

Imaging Neuromelanin and Iron in Dystonia/Parkinsonism

Status unknown Last updated 28 June 2018
What this trial tests

trial testing 3Tesla MRI in Sporadic Dystonia in 80 participants. Status unknown.

Timeline
1 July 2018
Primary endpoint
1 July 2021
1 July 2021

Quick facts

Lead sponsorUniversity College, London
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment80
Start date1 July 2018
Primary completion1 July 2021
Estimated completion1 July 2021

Drugs / interventions tested

Conditions studied

Sponsor

University College, London

Who can join

Adults 18 to 60, any sex, with Sporadic Dystonia or Dystonia, Familial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To generate pilot data to investigate the potential to use in vivo iron- and neuromelanin-quantification as imaging tools for the diagnostic evaluation of movement disorders with predominant dystonia / parkinsonism. To this end we are planning to compare the MR imaging neuromelanin and iron-pattern and content in midbrain, striatum and further brain structures in clinically similar entities and respective, sex- and age-matched healthy controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University College, London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03572114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing